GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Itoco Inc (OTCPK:ITMC) » Definitions » Gross-Profit-to-Asset %

Itoco (ITMC) Gross-Profit-to-Asset % : 0.41% (As of Sep. 2010)


View and export this data going back to 2009. Start your Free Trial

What is Itoco Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Itoco's annualized Gross Profit for the quarter that ended in Sep. 2010 was $0.01 Mil. Itoco's average Total Assets over the quarter that ended in Sep. 2010 was $1.96 Mil. Therefore, Itoco's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2010 was 0.41%.


Itoco Gross-Profit-to-Asset % Historical Data

The historical data trend for Itoco's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Itoco Gross-Profit-to-Asset % Chart

Itoco Annual Data
Trend Dec08 Dec09
Gross-Profit-to-Asset %
75.93 4.70

Itoco Quarterly Data
Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 14,147.37 -52.02 3.49 0.15 0.41

Competitive Comparison of Itoco's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Itoco's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Itoco's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Itoco's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Itoco's Gross-Profit-to-Asset % falls into.



Itoco Gross-Profit-to-Asset % Calculation

Itoco's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2009 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2009 )/( (Total Assets (A: Dec. 2008 )+Total Assets (A: Dec. 2009 ))/ count )
=0.211/( (5.697+3.28)/ 2 )
=0.211/4.4885
=4.70 %

Itoco's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2010 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2010 )/( (Total Assets (Q: Jun. 2010 )+Total Assets (Q: Sep. 2010 ))/ count )
=0.008/( (2.012+1.915)/ 2 )
=0.008/1.9635
=0.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2010) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Itoco Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Itoco's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Itoco (ITMC) Business Description

Traded in Other Exchanges
N/A
Address
50 West Liberty Street, Suite 880, Reno, NV, USA, 89501
Itoco Inc is focused on developing and bringing biotech products to the market via co-development and joint venture arrangements with various companies. The company is currently examining various technologies that seek to control and/or identify bio-contaminants such as viruses and bacteria.